STUDY DESIGN: Technique description and retrospective data analysis. PURPOSE: To describe the technique of cervical kyphosis correction with partial facetectomies and evaluate the outcome of single-stage posterior decompression and kyphosis correction in multilevel cervical myelopathy. OVERVIEW OF LITERATURE: Kyphosis correction in multilevel cervical myelopathy involves anterior and posterior surgery. With the advent of cervical pedicle screw-rod instrumentation, single-stage posterior kyphosis correction is feasible and can address stretch myelopathy by posterior shortening. METHODS: Nine patients underwent single-stage posterior decompression and kyphosis correction for multilevel cervical myelopathy using cervical pedicle screw instrumentation from March 2011 to February 2014 and were evaluated preoperatively and postoperatively with modified Japanese Orthopaedic Association (mJOA) scoring and computed tomography scans for radiological measurements. Kyphosis assessment was made with Ishihara curvature index and C2–C7 Cobb's angle. The linear length of the spinal canal and the actual spinal canal length were also evaluated. The average follow-up was 40.56 months (range, 20 to 53 months). RESULTS: The average preoperative C2–7 Cobb's angle of 6.3° (1° to 12°) improved to 2° (10° to −9°). Ishihara index improved from −15.8% (−30.5% to −4.7%) to −3.66% (−14.5% to +12.6%). The actual spinal canal length decreased from 83.64 mm (range, 76.8 to 91.82 mm) to 82.68 mm (range, 75.85 to 90.78 mm). The preoperative mJOA score of 7.8 (range, 3 to 11) improved to 15.0 (range, 13 to 17). CONCLUSIONS: Single-stage posterior decompression and kyphosis correction using cervical pedicle screws for multilevel cervical myelopathy may address stretch myelopathy, in addition to decompression in the transverse plane. However, cervical lordosis was not achieved with this method as predictably as by the anterior approach. The present study shows evidence of mild shortening of cervical spinal canal and a positive correlation between canal shortening and clinical improvement.
Animals ; Asian Continental Ancestry Group ; Decompression ; Follow-Up Studies ; Humans ; Kyphosis* ; Lordosis ; Methods ; Pedicle Screws* ; Retrospective Studies ; Spinal Canal ; Spinal Cord Diseases* ; Statistics as Topic

The body condition score (BCS) system is a subjective scoring method of evaluating the energy reserves of dairy animals to provide better understanding of biological relationships between body fat, milk production and reproduction. This method helps in adopting the optimum management practices to derive maximum production and maintain optimum health of the livestock. In this study, a new BCS system was developed for Murrah buffaloes. The skeletal check points were identified by studying the anatomical features and amount of fat reserves in slaughtered animals. The scores were assigned from 1 to 5 based on the amount of fat reserves in slaughtered animals. A score of 1 represents least and 5 represents most amount of fat. The skeletal check points identified were ordered based on the amount of carcass fat reserves and scores assigned to prepare a preliminary BCS chart on a 1 to 5 scale at 0.25 increments. The BCS chart was further modified by eliminating the skeletal check points at which the fat reserves were less evident on palpation in most of the buffaloes and a new BCS chart on a 1 to 5 scale at 0.5 increments examining eight skeletal check points was developed. The new BCS system developed was tested for precision in 10 buffaloes for each point of the 1-5 scale by ultrasonographic measurements of body fat reserves. Ultrasonographic measurements showed that as the BCS increased, the amount of fat reserves also increased (p < 0.01), indicating that the BCS adequately reflected the amount of actual fat reserves. BCS was significantly correlated (r = 0.860) with the carcass fat reserves as well as the ultrasonographic fat reserves (r = 0.854).
Adipose Tissue/*physiology/ultrasonography ; Animals ; Body Composition/*physiology ; Buffaloes/*physiology ; Dairying ; Female

Activated pancreatic stellate cells (PSCs) have been widely accepted as a key precursor of excessive pancreatic fibrosis, which is a crucial hallmark of chronic pancreatitis (CP) and its formidable associated disease, pancreatic cancer (PC). Hence, anti-fibrotic therapy has been identified as a novel therapeutic strategy for treating CP and PC by targeting PSCs. Most of the anti-fibrotic agents have been limited to phase I/II clinical trials involving vitamin analogs, which are abundant in medicinal plants and have proved to be promising for clinical application. The use of phytomedicines, as new anti-fibrotic agents, has been applied to a variety of complementary and alternative approaches. The aim of this review was to present a focused update on the selective new potential anti-fibrotic agents, including curcumin, resveratrol, rhein, emodin, green tea catechin derivatives, metformin, eruberin A, and ellagic acid, in combating PSC in CP and PC models. It aimed to describe the mechanism(s) of the phytochemicals used, either alone or in combination, and the associated molecular targets. Most of them were tested in PC models with similar mechanism of actions, and curcumin was tested intensively. Future research may explore the issues of bioavailability, drug design, and nano-formulation, in order to achieve successful clinical outcomes with promising activity and tolerability.